Log in
OTCMKTS:AVDX

Avant Diagnostics Stock Forecast, Price & News

$0.03
+0.00 (+6.31 %)
(As of 05/9/2019)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range
$0.03
MA: $0.03
$0.03
52-Week Range
$0.00
Now: $0.03
$0.08
Volume38,500 shs
Average Volume12,100 shs
Market Capitalization$10.78 million
P/E RatioN/A
Dividend YieldN/A
Beta9.42
Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AVDX
CUSIPN/A
CIKN/A
Phone708-710-9200
Employees2

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.01 per share

Profitability

Net Income$-2,370,000.00

Miscellaneous

Market Cap$10.78 million
Next Earnings DateN/A
OptionableNot Optionable
$0.03
+0.00 (+6.31 %)
(As of 05/9/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive AVDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avant Diagnostics (OTCMKTS:AVDX) Frequently Asked Questions

How has Avant Diagnostics' stock price been impacted by COVID-19?

Avant Diagnostics' stock was trading at $0.0320 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVDX shares have increased by 0.0% and is now trading at $0.0320.
View which stocks have been most impacted by COVID-19
.

Who are some of Avant Diagnostics' key competitors?

What other stocks do shareholders of Avant Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avant Diagnostics investors own include Bottomline Technologies (de) (EPAY), Sysco (SYY), American Airlines Group (AAL), AnaptysBio (ANAB), Aptevo Therapeutics (APVO), American Railcar Industries (ARII), The Boeing (BA), Biogen (BIIB), BankUnited (BKU) and Cray (CRAY).

Who are Avant Diagnostics' key executives?

Avant Diagnostics' management team includes the following people:
  • Mr. Jeffrey M. Busch, Exec. Chairman (Age 59)
  • Dr. Michael I. Ruxin, Pres, CEO & Director (Age 73)
  • Mr. Scott VanderMeer, Interim Chief Financial Officer (Age 32)
  • Dr. Glenn D. Hoke Ph.D., Chief Scientific Officer
  • Ms. Rene A. Schena, Chairman & CEO of Arrayit Corp. (Age 56)

What is Avant Diagnostics' stock symbol?

Avant Diagnostics trades on the OTCMKTS under the ticker symbol "AVDX."

How do I buy shares of Avant Diagnostics?

Shares of AVDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avant Diagnostics' stock price today?

One share of AVDX stock can currently be purchased for approximately $0.03.

How big of a company is Avant Diagnostics?

Avant Diagnostics has a market capitalization of $10.78 million and generates $250,000.00 in revenue each year. Avant Diagnostics employs 2 workers across the globe.

What is Avant Diagnostics' official website?

The official website for Avant Diagnostics is avantdiagnostics.com.

How can I contact Avant Diagnostics?

Avant Diagnostics' mailing address is 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007. The company can be reached via phone at 708-710-9200 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.